The name AllStripes Research was inspired by the symbol for the rare disease community, the zebra. When we come together and learn from each other’s experiences we can push for better treatments across all rare conditions.
We are a Public Benefit Corporation co-founded in 2017 by CEO Nancy Yu and Onno Faber, a rare disease patient deeply frustrated by the drug development process.
As the leading research platform dedicated to rare diseases, AllStripes makes it easy for patients to contribute to new treatment research from home. We do the work to collect and analyze de-identified medical records to help power faster, better drug development.
We partner with rare disease patient advocacy organizations and key opinion leaders to build our programs. Our expert researchers produce original research insights and publications, as well as partner with academic institutions and pharmaceutical companies to make progress towards new treatments.
"My interest in rare disease research originated from the challenges that my father and family faced against a rare prostate cancer. I empathize with our AllStripes patients and families, who continue to fight like my family did, day after day."
“My close family member was diagnosed with a rare neurodevelopmental disease in early childhood. My family’s experience inspired me to pursue a career in science so I could research new therapies for patients with few treatment options.”